Kalamazoo, MI, United States of America

Wade J Adams

This inventor holds 3 USPTO granted patents. Top assignees: Pharmacia & Upjohn Company, The Upjohn Co.. Active years: 1982-2005.


% Patents Active = 66.7

Average Co-Inventor Count = 2.1

ph-index = 2

Forward Citations = 41(Granted Patents)


Company Filing History:


Years Active: 1982-2005

Loading Chart...
3 patents (USPTO):Explore Patents

Title: Wade J Adams: Innovator in Antibacterial Agents

Introduction

Wade J Adams is a notable inventor based in Kalamazoo, MI (US). He has made significant contributions to the field of antibacterial agents, holding a total of 3 patents. His work focuses on developing innovative compounds that target infectious diseases caused by various bacteria.

Latest Patents

Adams' latest patents include "Difluorothioacetamides of oxazolidinones as antibacterial agents." This invention describes difluorothioacetamide oxazolidinones that are effective in treating infectious diseases caused by both gram-positive and gram-negative bacteria. Another significant patent is related to "Thioalkyl alpha substituted pyrimidine compounds," which involves pyrimidine-thioalkyl and alkylether compounds that have potential therapeutic applications.

Career Highlights

Throughout his career, Wade J Adams has worked with prominent companies such as Pharmacia & Upjohn Company and The Upjohn Company. His experience in these organizations has contributed to his expertise in the development of pharmaceutical innovations.

Collaborations

Adams has collaborated with notable individuals in his field, including Mikhail Fedor Gordeev and Janice M Friis. These partnerships have likely enhanced his research and development efforts.

Conclusion

Wade J Adams is a distinguished inventor whose work in antibacterial agents has the potential to impact public health significantly. His innovative patents and collaborations reflect his commitment to advancing medical science.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…